SETD2 and acute myeloid leukemia: Our finding of discriminative SETD2 mutations in 11q23/KMT2A‐rearranged pediatric AML suggested that cytarabine‐based chemotherapy in combination with checkpoint inhibitors might provide a promising therapeutic strategy for refractory 11q23/KMT2A‐rearranged pediatric AML patients with chemoresistance.